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Abstract 
 
Background: Irrational use of medicines is widespread in the South-East Asia Region (SEAR), where policy implementation 
to encourage quality use of medicines (QUM) is often low. The aim was to determine whether public-sector QUM is better 
in SEAR countries implementing essential medicines  (EM) policies than in those not implementing them. 
Methods: Data on six QUM indicators and 25 EM policies were extracted from situational analysis reports of 20 
country  (2-week) visits made during  2010–2015. The average difference  (as percent) for the QUM indicators 
between countries implementing  versus not implementing  specific policies was calculated. Policies associated 
with better (> 1%) QUM were included in regression of a composite  QUM score versus total number of policies 
implemented. 
Results: Twenty-two  policies were associated with better (> 1%) QUM. Twelve policies were associated with 3.6– 
9.5% significantly  better  use (p < 0.05), namely: standard treatment guidelines; formulary; a government  unit to 
promote QUM; continuing  health worker education on prescribing by government; limiting over-the-counter 
(OTC) availability  of systemic antibiotics; disallowing public-sector prescriber revenue from medicines sales; not 
charging  fees at the point of care; monitoring advertisements of OTC medicines; public education on QUM; and a 
good drug supply system. There was significant correlation between the number of policies implemented out of 
22 and the composite  QUM score (r = 0.71, r2 = 0.50, p < 0.05). 
Conclusions: Country situational analyses allowed rapid data collection that showed EM policies are associated 
with better QUM. SEAR countries should implement  all such policies. 
Keywords: South-East Asia, Quality use of medicines, Essential medicines policy 
 
 
Background 
Inappropriate (irrational,  incorrect,  improper,  poor  qual- 
ity) use of medicines is a serious public health problem 
world-wide  [1–5]  that  wastes  resources  and  may  result 
in treatment failure and avoidable adverse drug events, 
including  antimicrobial  resistance  [6–8],  hospitalisation 
and   death   [9–11].   The   World   Health   Organisation 
(WHO) has been promoting the concept  of essential 
medicines   and  a  range  of  policies  to  promote   better 
quality  (rational)   use  of  medicines   (QUM)   for  many 
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years [12, 13]. The  extent  to which  countries,  including 
many  in  South-East   Asia,  monitor  use  or  implement 
these recommended policies vary greatly [14, 15]. A re- 
view of  interventions  to  promote   better   QUM  in  low 
and  middle-income  countries   found  that  relatively  few 
had  been  implemented and  that  most  were  small  scale 
of short  duration  with small or modest  effect [4, 5]. 
Analysis of secondary  data  on public-sector medicines 
use in primary  care (from WHO’s  database  of medicines 
use surveys) and policy implementation as reported  by 
Ministries  of Health  (MOH)  (from  questionnaires sent 
to Ministries  of Health  by WHO)  showed  that  many es- 
sential   medicines   policies   are   associated   with   better 
QUM  and  that  the  more  policies  are  implemented the 
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better  the use [16, 17]. Policies most  strongly  associated 
with QUM  were: undergraduate training  of doctors  and 
nurses  in standard treatment guidelines,  the  ministry  of 
health having a unit promoting QUM, and provision of 
essential  medicines  free  at  point  of care  to  all patients 
[16, 17]. 
The need for an integrated health systems approach, 
incorporating regular  monitoring of medicines  use  and 
the  sustainable  implementation of multiple  policies  has 
long been recognised  [18, 19]. However, development of 
such   an  approach   remains   elusive  in  many  low  and 
middle-income countries, where data are scant, infra- 
structure is lacking and responsibility for medicines 
management  often  falls between  different  departments 
with no clear accountability  [20]. 
Since  2010  South-East  Asian  countries of the  WHO 
have been undertaking 4-yearly rapid situational  analyses 
of how medicines  are used  and  managed  with a view to 
developing  a  more  integrated,   coordinated  health  sys- 
tems   approach   to  promoting  better   QUM   [21].  This 
process consists of rapid systematic data collection on 
medicines use and policy implementation by a multi- 
disciplinary  government  team  of  four  to  eight  people 
over  2 weeks  using  a  predesigned   workbook  tool  and 
ending  with  a national  workshop  to  identify  priorities 
for action  [21]. During  2010–2015,  all 11 jurisdictions 
(all  South-East   Asia  countries   including   two  Indian 
States)  had  conducted at least  one  situational  analysis; 
eight   had   conducted  two   situational   analyses   sepa- 
rated   by  a  period   of  4  years;  and  the  reports   pub- 
lished on the WHO’s South-East Asia Regional Office 
(SEARO) website  after  government approval  [21]. 
The aim of this paper was to investigate associations 
between  the  adoption  (implementation or partial  imple- 
mentation)  of  national   policies   intended   to   improve 
QUM  and patterns of medicine  use in WHO  South-East 
Asian  countries.   The  analysis  relies  on  data  on  medi- 
cines use in public-sector primary care, and policy im- 
plementation, extracted  from the country  situational 
analysis reports  [21]. Specific objectives were to establish 
for the WHO  South-East  Asia region: 
 
1.   which policies are associated with better QUM, 
2.   whether  the implementation of more policies is 
associated with better QUM, and 
3.   whether  there was any improvement in policy 
implementation and QUM in countries  that had 
undertaken  two situational analyses. 
 
Methods 
The country  reports  of the situational  analyses published 
on   the   website   of   the   WHO    Regional   Office   for 
South-East  Asia (WHO/SEARO) [21] were reviewed and 
data  extracted   on  QUM  in  public-sector  primary  care 
and the implementation of policies to encourage  appro- 
priate  use. The  methods   for  conducting  country   situ- 
ational   analyses  have  been   described   elsewhere   [21, 
22]  and  are  summarised  in  Table  1.  Briefly, data  on 
policy implementation was collected by interviews of 
health staff and observation,  and data on QUM by 
prescription  survey  following  the   International  Net- 
work for the Rational Use of Drugs (INRUD)/WHO 
methodology  [23, 24] at all the  health  facilities visited. 
The   methods    used   to   analyse   the   extracted    data 
followed similar  methods  used  by first  author  in 
analysing  global data  and  are  described  elsewhere  [16, 
17] and  summarised below. 
A dataset  was created  (Additional  file 1) consisting  of 
six standard QUM  indicators  [16, 17] and  indicators  for 
implementation of 25 policies hypothesised  to influence 
 
Table 1 Summary of methods used in a country situational 
analysis 
Background 
Development of the situational analysis approach in South-East Asia 
was requested by Member  States [38, 39] and involves the systematic 
collection of data by a government  multi-disciplinary  team over 2 
weeks using a pre-designed  workbook  tool [21] and supervised by 
WHO. The workbook  tool (Additional file 2) builds on other tools 
[14, 23, 24] and was developed by WHO/SEARO during  situational 
analyses done in 11 countries during 2010–13 and piloted for use by 
government  staff in eight countries during 2014–15. 
Methods 
Visits are made to: 
• all major MOH units and other agencies responsible for medicines 
management  (supply, selection, use, regulation,  policy, insurance 
and professional training) to understand what policies are in place 
and what each unit does. 
• healthcare facilities, aiming to visit 20 facilities, two of each type of 
public facility (primary care centres and sub-centres, secondary and 
tertiary hospitals, with half of the facilities being primary care 
centres) plus private pharmacies (results not reported in this paper) 
in at least two provinces/regions,  as selected by the MOH. 
Data collection and Analysis 
 
At the central level, staff are interviewed about the health system, 
what their unit does and what policies are in place. 
At each health facility (whether hospital or health centre), the team 
reviews 30 primary care outpatient  encounters (using whatever 
documentation  is available at the facility, e.g. prescriptions held in the 
pharmacy or by the patient, paper slips in the pharmacy, patient 
records, or outpatient registers). The means for standard indicators of 
medicines use [23, 24] are calculated for each facility and each 
category of facility. Also, antibiotic  use in 30 outpatient cases of upper 
respiratory tract infection is reviewed, although  this is difficult in some 
countries where diagnosis is not recorded on the prescription. The 
basis for a diagnosis of upper respiratory tract infection is also 
recorded e.g. acute viral respiratory infection, pharyngitis, sore throat, 
rhinitis, runny nose, cough, cold, otitis media, earache, sinusitis, acute 
laryngitis and acute bronchitis. 
The medicines’ supply and regulatory systems are also reviewed and 
health workers interviewed about medicine management policy 
implementation. 
A descriptive analysis is done each day and presented by the team at 
a national workshop at the end of 2 weeks, and a country  report 
published on the WHO/SEARO website after government approval 
[21, 38]. 
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medicines  use [14–17], derived from  data  collected  dur- 
ing 20 country  situational  analysis visits. Since different 
provinces  or  regions  and  different  healthcare   facilities 
were visited in the  countries  where  two situational  ana- 
lyses  were  done,  and  the  visits  were  separated   by  3– 
5 years (during  which time  the  implementation of some 
policies changed),  these situational  analyses were treated 
as separate records (country-year jurisdictions)  in the 
dataset. 
The  QUM  indicators   (described  in  Table  2, together 
with   the   direction   of  more   appropriate  use)   are   all 
expressed as proportions and include all the indicators 
measured  in the  country  situational  analyses apart  from 
one (the average number  of drugs per patient). In the 
situational  analysis reports  [21], QUM indicators  were 
reported  as an average for each facility type, but  for this 
analysis  one  result  per  QUM  indicator  was  calculated, 
this being the average across all facilities. 
The policy indicators  (described in Table 3) are all 
expressed   as  categorical  yes/no  variables  and  include 
all those  policies  hypothesised   to  improve  the  appro- 
priate use of medicines [16, 17] for which data were 
available  in  the  country   situational   reports   [21]  and 
for  which  there  were  countries   with  and  without  the 
policy  (for  comparison).  Some   policies   hypothesised 
to influence prescribing  were not implemented by any 
country   (e.g.  monitoring  all  drug   promotional  activ- 
ities),  but   if  possible,   similar   more   limited   policies 
were substituted (e.g. monitoring of advertisements 
restricted to over-the-counter drugs). Where policy 
implementation  was  expressed   as  a  range   of  values, 
the  policy  was  converted   to  a  yes/no  value.  For  ex- 
ample,   “some”   public   education   and   “some”   health 
worker training was regarded as “yes” when assessing 
whether   a  country   had   implemented  these   policies. 
Details  of  decisions  on  whether  a  policy  was  marked 
as present  or  not  can  be seen  in Table  3. Since coun- 
try wealth may be a potential  confounder (being asso- 
ciated   with   both    better    QUM   and   greater    policy 
 
Table 2 Quality Use of Medicines (QUM) indicators and direction 
of better use 
QUM Indicator                                                        Direction of better 
                                                                           use 
implementation),  data   on  gross  national   income   per 
capita  (GNIpc)  were  extracted  for each  country  in the 
year   of   the    situational    analysis   from    the    United 
Nations  (UN)  Country  Profile  Data  [25]. 
 
Analyses 
Analyses were done  in Excel 2016 and  Epi Info version 
7.2.1.0. Univariate  analyses, with each policy as the  unit 
of analysis, were used to identify policies that  were asso- 
ciated with better  QUM. The mean difference (expressed 
as a percentage) for each QUM  indicator  between 
“countries” (country-year jurisdiction)  implementing and 
not implementing a specific policy was calculated. The 
directionality  of “better”  or  “worse”  use  was aligned  for 
each of the six QUM  indicators  and an average (overall) 
difference calculated for each specific policy, whereby a 
positive  (+) number  indicates  “better”  use  and  a minus 
(−) number indicates  “worse” use. The  mean  differences 
for  each   QUM   indicator,   and   the   average  difference 
across  all QUM  indicators  for  each  policy  were  calcu- 
lated   and   represent  an   estimate   of  the   quantitative 
impact  of each policy. Head-to-head comparisons of the 
impact  of different policies and further  multiple  compar- 
isons were not done. 
Correlations of multiple  policies with QUM indicators, 
where the “country-year jurisdiction” was the unit of 
analysis, were performed  to see if adoption  (implementa- 
tion or partial implementation) of more policies was 
associated  with  better  QUM.  Since  various  policies  are 
likely to impact  differently on different  QUM  indicators, 
and  to  gain  an  idea  of the  overall  impact  on  QUM  by 
the package of policies that  any one country  was imple- 
menting  in one specific year, a composite  QUM  variable 
was derived, in the same manner  as has been done  else- 
where [16]. Use of a composite  QUM variable allowed 
comparison  of  data   across   all  20  situational   analyses 
rather  than  only  15, since  some  QUM  indicators  were 
not  measured  in five situational  analyses. For each indi- 
vidual QUM  variable, we calculated  how  far that  coun- 
try’s value (referred  to  as “country-year”  – see text)  lay 
above or below the  mean  value from  all “country-years” 
and  then  converted   this  difference  into  standard devi- 
ation units. The average of the standard deviation unit 
increments  across   all  six  QUM   indicators   for   each 
% Upper Respiratory Tract Infection  (URTI) cases 
(patients) treated with antibiotics 
Less country-year was calculated  and  this was then  regressed 
against  the  number   of implemented  policies  that  were 
% cases (patients)  treated  with antibiotics  Less associated  with an effect size of more than  1% (22 out of 
% prescribed medicines from the national Essential 
Medicines  List (EML) 
More 25 policies) as estimated  from the univariate  analysis. 
Although  countries  implement each  policy differently, 
% medicines prescribed by generic name More 
% cases (patients)  treated  with multivitamins Less 
% cases (patients)  treated  with an injection Less 
Six standard indicators of quality of medicines use [23, 24] expressed  as 
proportions and reported in 85–100% of the situational analyses 
the adoption  of more  policies is likely to reflect stronger 
intention to promote  QUM, which may be reflected 
variously by different  QUM indicators.  Hence, individual 
QUM indicators were also regressed on the number of 
policies  a  country   implemented.  Since  there   may  be 
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Table 3 Medicine Policy variables with information on how a policy was judged  to be present or not 
Policies recommended  to improve medicines usea Criteria to determine whether a policy was adopted (implemented  or partially 
implemented) in a country 
National structures, medicines policies and monitoring 
1    National MOH unit on promoting  rational use of medicines Policy was marked “yes” if there was any unit, even if very small and consisting of 
only 1–2 persons, or an executive committee with responsibility for promoting quality 
use of medicines. 
 
2    Presence of a Drug and Therapeutic Committee (DTC) in 
most referral hospitals 
 
Policy was marked “yes” if more than half of referral hospitals visited had a DTC 
which had met in the last year (even if not very active) and there was an MOH 
mandate for DTCs. 
3    National strategy to contain antimicrobial resistance Policy was marked “yes” if there was any policy document  endorsed by MOH on 
AMR containment. 
 
4    Presence of National Drug Information Centre Policy was marked “yes” if any national drug information  centre existed, even if the 
centre was not very active and did not offer 24-hour emergency information. 
5    Prescription audit in the last 2 years Policy was marked “yes” even if the audit had only been undertaken in the health 
facilities of some districts, but including at least one of the districts visited during 
the situational  analysis. 
Educational policies 
6    Undergraduate training of prescribers on the National 
Essential Medicines  List (EML) 
7    Undergraduate training of prescribers on the National 
Standard Treatment Guidelines (STGs) 
8    Continuing medical education (CME) of prescribers by 
MOH 
 
 
Policy was marked “yes” even if only some training institutions included the EML in 
the curriculum. 
Policy was marked “yes” even if only some training institutions included the STG in 
the curriculum. 
Policy was marked as “yes” even if only some prescribers received CME on general 
prescribing in adults and/or children. The Antibiotic SMART Use program in 
Thailand, INRUD training  activities in Nepal and the training activities of the 
National Institute of Health  (INS) in Timor-Leste are examples of CME by the MOH 
[21, 37]. 
9    Public education on medicines use in last 2 years Policy was marked “yes” if any district populations had received public education. 
Managerial Policies 
10  National Essential Medicines List updated  in the last 2 years   Was not hypothesized to influence antibiotic  use. 
11  National Standard Treatment Guidelines updated in the last 
2 years 
 
12  National Standard Treatment Guidelines (STGs) found in 
some health facilities (indicator of STG implementation). 
Policy was marked” yes” if there was any kind of officially published book 
containing national treatment guidelines, but not for disease protocols  on posters 
or pamphlets. 
 
Policy was marked “yes” if the national STGs (published book) were observed in 
more than two facilities visited. 
13  National Formulary available Policy was marked “yes” if any national formulary was observed in any facility. 
 
14  Generic prescribing policy in public sector Policy was marked “yes” if there was any initiative described to encourage generic 
prescribing. Was not hypothesized to influence antibiotic  use. 
15  Generic substitution in public sector Policy was marked “yes” if generic substitution was both legal and seen to occur. 
Was not hypothesized to influence antibiotic  use. 
 
16  Prescriber workload low or moderate Low/moderate workload defined as less than 60 patients per prescriber per day, as 
reported by prescribers or as observed  in patient registers. 
Supply system 
17  Public sector procurement limited to only EML medicines    Policy was marked “yes” if public sector procurement limited to EML medicines  was 
reported at the central level and observed at the health facilities visited. Indicator of 
implementation of the EML. 
 
18  No medicines stock-out problems reported in the health 
facilities visited 
 
Economic Policies 
 
19  NO Drug  sales revenue  used to supplement prescriber 
income 
 
Policy was marked “yes” if health workers at the facilities visited stated that there 
were no stock-out problems. Indicator of the quality of the supply system which 
may impact on use. 
 
 
Policy was marked “no” if prescribers were observed selling drugs in the public 
sector, as was the case in one country in 1 year. 
20  No registration or consultation fee All countries stated that they dispensed drugs free of charge to all patients in 
public facilities if medicines were available, but some charged registration or 
consultation fees which could be perceived by patients as payment  for treatment. 
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Table 3 Medicine Policy variables with information on how a policy was judged  to be present or not (Continued) 
Policies recommended  to improve medicines usea Criteria to determine whether a policy was adopted (implemented  or partially 
implemented) in a country 
21  No user fee or copayment at the point of care Although all countries officially dispensed drugs free of charge in public facilities, 
some types of facility, generally hospitals, charged a user fee or co-payment for 
drugs at the point of care. 
Regulatory policies 
 
22  Systemic antibiotics generally not available over-the- 
counter  (OTC) 
 
 
Systemic antibiotics could be got OTC in all countries but were generally 
unavailable in Bhutan  and DPR Korea where  the private sector is very small, and 
effort is made to enforce the drug schedules. 
23  Regulation of advertisements for OTC drugs medicines No countries were monitoring  all drug promotional  activities, but some did monitor 
advertising of OTC drugs. 
Human resource policies 
 
24  Prescribing by doctors (as opposed  to other staff) in public 
primary care 
 
 
25  No prescribing by staff with less than 1 month’s training 
in public primary care 
 
 
Policy was marked “yes” if doctors were observed to be prescribing in the primary 
care facilities visited. Where doctors were not prescribing paramedical staff or 
nurses generally prescribed, although  in one country unqualified staff sometimes 
prescribed. 
Policy was marked “yes” if no unqualified staff were observed to prescribe. 
aIncludes all the policy questions, hypothesised to act on the quality of medicines use, as hypothesised  elsewhere [16, 17] and found in the situational analysis 
reports [21] 
 
 
correlation between the results of different situational 
analyses done  in the  same  country,  a sensitivity analysis 
was done by restricting  the regression  analysis to the lat- 
est situational  analysis of the country. 
The  impact  of country  economic  status  was assessed 
by including  Gross  National  Income  per  capita  (GNIpc) 
into  multiple  linear regression  analyses and by repeating 
the  regression  analyses for countries  with  GNIpc  above 
and below the median  of USD 2230. 
Finally, in those  countries  where  a situational  analysis 
was done  twice, the mean  difference between  situational 
analyses, for each of the six QUM  indicators,  was calcu- 
lated to see whether  there  had been any change in QUM 
over time, and whether  any change  was accompanied by 
a corresponding change in the number  of policies 
implemented. 
 
Results 
Data were extracted from 20 situational analysis reports 
covering all 11 countries of the WHO  South-east Asia 
region  –  two  reports  from  eight  countries in  different 
years, two reports  from India (one North  Indian  and one 
South Indian  state in the same year) and one report  each 
from    two   countries    (Democratic    Peoples’   Republic 
[DPR] of Korea and Indonesia).  QUM  data for all six in- 
dicators   were  extracted   from  15  country-visit   reports, 
with 1–2 QUM variables missing from four reports 
(concerning injection use, prescribing from the Essential 
Medicines List [EML] and antibiotic  use in upper re- 
spiratory  tract  infection  [URTI] cases), and  5 out  of six 
QUM  indicators  missing  from  one  early  report 
(Bangladesh 2010). A total of 206 public-sector health 
facilities  were  visited  (average  of  10–11  public-sector 
health  facilities per country-visit,  half of which were pri- 
mary healthcare  centres)  and 30 prescriptions per facility 
were examined  to estimate  five of the  six QUM  indica- 
tors.  The  QUM  indicator  concerning the  % URTI cases 
treated  with antibiotics  was estimated  from  visits to 151 
public-sector  health  facilities  (average  of  7–8  facilities 
per  country  visit) with an average of 23 URTI prescrip- 
tions  examined  per  facility. In two countries  (Sri Lanka 
2010 and  Bangladesh  2010) no data  on antibiotic  use in 
URTI was available, in two countries (Bhutan 2011 and 
Maldives 2011) data on antibiotic  use in URTI was avail- 
able in only two health facilities and in one country 
(Indonesia  2011) from  only three  health  facilities. Policy 
data  for  all  25  indicators   were  extracted   from  all  20 
country-visit  reports. 
 
Comparison of QUM indicators in countries with and 
without  specific policies 
Table  4 shows  the  mean  differences  for each  of the  six 
QUM  indicators,  and  the  average  difference  across  all 
six QUM  indicators,  between  countries  that  did and did 
not implement the 25 policies hypothesised  to be associ- 
ated with better  use. Figure 1 shows the mean  difference 
(with 95% confidence  interval)) across all six QUM  indi- 
cators  for each of the 25 policies. Twenty-two  out  of 25 
policies  were  associated  with  better  QUM,  although  in 
many  cases  the  differences  were  small.  Twelve  policies 
were  associated  with  statistically  significantly  (p < 0.05) 
better  QUM  of more  than  3.6% – namely  not  charging 
patients  any user  fee or copayment  for medicines  at the 
point  of care, undergraduate education  of prescribers  on 
the national  treatment guidelines  (STGs), distribution of 
STGs  to  health   facilities  (as  demonstrated  by  finding 
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Table 4 Differences in medicine use between countries with and without each of 25 policies hypothesised to be associated with 
better use 
Policy Number of 
countries with 
policy 
(out of 20)a 
% URTI 
cases 
treated with 
antibiotics 
% patients 
treated 
with 
antibiotics 
% medicines 
prescribed 
from the 
EML 
% medicines 
prescribed by 
generic name 
% patients 
prescribed 
multivitamins 
% of 
patients 
prescribed 
injections 
Average % better 
(+) medicines use 
with policy 
(95% CI) 
Direction of better 
medicines  use: 
More (+); Less (−) 
No user fee for drugs 
at most public health 
facilities 
 
Undergraduate 
education of 
prescribers on STGs 
Systemic antibiotics 
mostly not available 
OTC 
 
MOH unit on Rational 
Use of Medicines 
established 
Some public-sector 
prescriber  CME by 
MOH 
Advertisements for 
OTC drugs monitored 
 
Public sector generic 
prescribing policy 
No drug revenue for 
public sector 
prescribers 
MOH prescribing 
survey done in the last 
2 years 
 
STGs found in some 
public health facilities 
No public-sector 
registration or 
consultation fee 
 
Some public education 
on medicines use in 
the last 2 years 
 
DTCs in most public 
referral hospitals 
Generic substitution in 
the public sector 
No drug stock-out 
problems reported 
National Formulary 
available 
National  EML updated 
in the last 2 years 
 
Undergraduate 
education of doctors 
on the EML 
No public-sector un 
qualified prescribers 
National STG updated 
in the last 2 years 
Less (−) Less (−) More (+) More (+) Less (−) Less (−) Sign changed 
where  less use is 
better use 
17 −9.6 + 0.1 + 9.5 + 31.2 −7.5 + 0.8 9.5* (0.2 to 18.7) 
 
 
5 −15.9 −5.2 + 12.0 + 22.0 − 1.1 + 0.9 9.2* (2.1 to 16.4) 
 
 
3 −16.0 − 5.2 + 12.0 + 22.0 − 1.3 + 1.4 9.2* (1.9 to16.4) 
 
 
3 −17.3 −10.9 + 0.1 + 19.7 + 0.9 −6.9 9.0* (2.1 to 15.9) 
 
 
8 −7.5 −1.6 + 5.7 + 21.9 − 8.7 − 4.8 8.4* (2.7 to 14.0) 
 
 
7 −14.5 −3.8 + 4.0 + 15.5 − 2.0 − 8.3 8.0* (3.4 to 12.7) 
 
9 −3.9 −1.6 + 9.8 + 35.1 + 0.4 + 2.2 8.0 (− 3.2 to 19.1) 
 
19 −19.1 −2.7 −2.2 + 18.8 − 7.0 −6.7 7.8* (0.1 to 15.5) 
 
 
7 −4.7 −1.2 + 4.6 + 28.6 + 2.7 − 7.7 7.4 (− 1.4 to 16.2) 
 
 
5 − 11.4 −9.7 + 6.1 + 17.8 + 1.4 + 2.4 6.9* (0.6 to 13.1) 
 
12 −13.0 −3.3 + 5.6 + 15.2 + 2.5 − 5.6 6.7* (1.5 to 11.9) 
 
 
5 −11.7 −7.4 + 2.5 + 8.9 −5.0 + 2.4 5.5* (1.5 to 9.5) 
 
 
8 −1.7 + 3.2 −2.5 + 15.2 −9.3 − 10.3 5.1 (− 0.9 to 11.2) 
 
15 + 6.0 + 7.8 + 16.1 + 21.8 −2.8 + 0.4 4.4 (−5.2 to 14.0) 
 
9 −11.6 −3.8 −0.1 − 1.4 −2.3 − 7.9 4.5* (0.1 to 8.0) 
 
7 −8.7 −0.7 −3.4 + 6.1 − 5.9 − 3.7 3.6* (0.2 to 7.1) 
 
12 −6.0 −0.7 + 16.1 − 0.4 + 1.2 + 2.2 3.2 (− 2.4 to 8.7) 
 
6 −9.9 + 0.6 −3.5 + 1.7 −3.7 −6.8 3.0 (−0.9 to 6.9) 
 
 
18 −5.8 −6.5 + 8.4 + 9.8 + 8.4 + 8.6 2.3 (−4.5 to 9.0) 
 
7 + 5.8 + 6.9 + 6.9 + 20.1 + 5.5 − 1.0 1.6 (−6.7 to 10.0) 
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Table 4 Differences in medicine use between countries with and without each of 25 policies hypothesised to be associated with 
better use (Continued) 
Policy Number of 
countries with 
policy 
(out of 20)a 
% URTI 
cases 
treated with 
antibiotics 
% patients 
treated 
with 
antibiotics 
% medicines 
prescribed 
from the 
EML 
% medicines 
prescribed by 
generic name 
% patients 
prescribed 
multivitamins 
% of 
patients 
prescribed 
injections 
Average % better 
(+) medicines use 
with policy 
(95% CI) 
National AMR 
Containment Strategy 
Public procurement 
limited to EML drugs 
only (excl. DPRK) 
National Drug 
Information Centre 
Public sector PHC 
prescribing by doctors 
Prescriber patient 
load moderate or 
low (< 60 patients 
/prescriber/day) 
*p ≤ 0.05 
4 −1.3 −3.7 −10.0 + 2.2 − 3.4 − 8.3 1.5 (− 3.4 to 6.4) 
 
15 + 12.6 + 12.5 + 15.5 + 22.3 + 0.2 + 3.4 1.5 (− 10.1 to 13.1) 
 
 
2 + 7.2 −1.5 −3.9 + 11.6 + 3.4 + 15.7 − 2.8 (− 10.1 to 4.4) 
 
13 + 1.9 + 3.5 −2.3 −10.3 −4.0 + 5.8 −3.3 (− 7.1 to 0.4) 
 
12 − 10.9 −8.7 −5.4 −6.3 + 27.2 + 7.9 − 4.5 (− 15.5 to 16.5) 
aSample size applies to the number of countries (out of 20) that had adopted the policy. The number of countries with and without policies for each individual 
QUM indicator varies slightly as certain QUM indicators  were not measured in 5 country visits 
OTC Over-the-counter, STG Standard treatment guidelines, MOH Ministry of health,  CME Continuing medical education, DTC Drug and therapeutic  committee,  EML 
Essential medicines list, AMR Antimicrobial resistance, DPRK Democratic People’s Republic of Korea (which had no published EML) 
 
them  in facilities), a Ministry of Health (MOH)  unit ded- 
icated to promoting QUM, continuing education  on 
prescribing    for   health    workers    by   MOH,    general 
non-availability of systemic antibiotics  over-the-counter 
(OTC),  monitoring  of  advertisements  for  OTC   medi- 
cines, no  revenue  from  medicine  sales for public  sector 
prescribers,  having  no  stock-out problems,  public 
education and  having  a national  formulary.  For the  22 
(out   of   25)   policies   associated   with   better   overall 
QUM  of more  than  1%, 96 (73%) of a possible  132 
comparisons  (6  QUM   indicators   × 22  policies)  were 
associated  with  better  QUM. 
 
 
 
Fig. 1 Differences in medicines use between countries with and without medicines policies. STG = Standard Treatment Guidelines; OTC = Over- 
the-Counter; MOH = Ministry of Health;  CME = Continuing Medical Education; DTC = Drug and Therapeutic Committee; EML = Essential Medicines 
List; AMR = Antimicrobial Resistance; PHC = Primary Health Care 
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Some   policies  had   large  effects  on   one   particular 
QUM  indicator,  but  not  on  overall  use  (as  judged  by 
six   QUM    indicators).    Generic    prescribing    policies 
were associated with greater generic prescribing; 
implementing the  national  EML (as indicated  by hav- 
ing an  updated  EML and  limiting  public  procurement 
to EML drugs)  was associated  with  greater  prescribing 
of EML medicines. However, low to modest prescriber 
workload  (as  defined  by  seeing  less  than  60  patients 
per day) was not associated with better overall QUM, 
although  it was associated  with  lower  antibiotic  use. 
 
Effects of multiple policies and national wealth 
Figure 2 shows a scatter  plot of the composite  QUM indi- 
cator  and  the  number of policies implemented (out  of 22 
policies associated with better QUM) for 20 situational  ana- 
lysis visits (country-years). There  was moderate  to  strong 
positive correlation between  the number  of essential medi- 
cines policies implemented and the composite  QUM  indi- 
cator  (r = 0.71,  r2 = 0.50,  p < 0.05).  In  sensitivity  analyses 
(not  shown  graphically)  the  correlation  increased   when 
GNIpc was included  in the regression  analysis (r = 0.75, r2 
= 0.57, p < 0.05) and the correlation was moderate  to strong 
in the 10 country-visits with GNIpc  above USD 2230 (r = 
0.76, r2 = 0.58, p < 0.05) and below USD 2230 (r = 0.69, r2 = 
0.48, p < 0.05). Furthermore, confining  the  regression  ana- 
lysis to data from the most recent  situational  analyses in 12 
states  (all 11 countries  including  2 Indian  states), in order 
to  take  account  of possible  clustering  of results  from  the 
same  site,  also  showed   moderate  to  strong   correlation 
between the composite  QUM indicator  and the number of 
essential medicines policies (r = 0.71, r
2 
= 0.50, p < 0.05). 
Figures  3,  4,  5,  6,  7  and  8  show  the  scatter   plots 
for the individual QUM indicators versus policy im- 
plementation. Regression analyses of individual QUM 
indicators  and the number  of policies (out of 22) im- 
plemented showed that with an increasing number  of 
essential   medicines   policies   implemented  there   was: 
an  increase  in  the  % prescribed   medicines   belonging 
to  the  EML  (r = 0.46,  r2 = 0.21,  p > 0.05)  (Fig.  3);  an 
increase   in   the   %  medicines   prescribed   by  generic 
name  (r = 0.62,  r
2 
= 0.38,  p < 0.05)  (Fig. 4);  a  decrease 
in the  % patients  prescribed  injections  (r = − 0.24, r2 = 
0.06, p > 0.05)  (Fig. 5)  and  a  decrease  in  the  % URTI 
cases   prescribed   antibiotics   (r = − 0.42,   r2 = 0.18,   p >  
0.05) (Fig. 6). There  was virtually no change in the % 
patients   treated   with   antibiotics   (r = − 0.1,  r2 = 0.01, 
p > 0.05)  (Fig.  7)  or  vitamins  (r = − 0.1,  r2 = 0.02,  p > 
0.05) (Fig. 8) with increasing  number  of policies im- 
plemented.  In a sensitivity analysis where policies not 
hypothesised  to  influence  antibiotic  use  were  excluded 
(2   policies   on   generic   prescribing    and   substitution 
and 3 policies on EML implementation), a stronger 
association  was found  between  the  number  of policies 
(out  of  17)  implemented  and  the  % URTI  cases  pre- 
scribed  antibiotics  (r = − 0.49, r2 = 0.24, p < 0.05). 
 
Changes over time 
In seven of the  eight  countries  where  a situational  ana- 
lysis had  been  done  twice, separated  by a period  of 3– 
 
 
 
Fig. 2 Scatter plot of composite  QUM score versus number  of policies (out of 22) implemented 
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Fig. 3 % prescribed medicines from the Essential Medicines List versus number  of policies (out of 22) implemented 
 
 
 
 
 
 
 
 
 
 
Fig. 4 % medicines prescribed by generic name versus number  of policies (out of 22) implemented 
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Fig. 5 % patients prescribed injections versus number  of policies (out of 22) implemented 
 
 
5  years,  the  average  mean   differences  over  time  for 
the   six  individual   QUM   indicators   and   the   average 
mean   difference   over   the   six  QUM   indicators,   to- 
gether with any change in the number  of policies im- 
plemented are  shown  in  Table  5.  The  data  for 
Bangladesh   were   excluded   because   five  of   the   six 
QUM   indicators    were   missing   from   the   first   situ- 
ational analysis in 2010. The data show a significant 
improvement in QUM together  with increased policy 
implementation  in  Thailand,   while  in  other  countries 
there was no significant change in QUM and policy 
implementation.   However,    the    small    sample    sizes 
 
 
 
Fig. 6 % Upper Respiratory Tract Infection  cases prescribed  antibiotics  versus number  of policies (out of 22) implemented 
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Fig. 7 % patients prescribed antibiotics  versus number  of policies (out of 22) implemented 
 
 
(concerning   health   facilities  and   patient   encounters) 
preclude  further  interpretation of the  data. 
 
Discussion 
This study has two important findings. Firstly, some pol- 
icies were associated  with significantly better  QUM; and 
secondly  the  more  of  these  policies  a  country   imple- 
mented  the better  was the QUM. 
Policies  statistically  significantly  associated  with  more 
than  7% better  overall QUM  were: not  charging  patients 
any user fee or co-payment for medicines  at the point  of 
care;  implementation  of  STGs  through  undergraduate 
 
 
 
Fig. 8 % patients prescribed vitamins versus number  of policies (out of 22) implemented 
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Table 5 Changes over time in 8 countries where two country  situational  analyses were done 
Country  (Years of 
country situational 
analyses) 
% URTI cases 
treated with 
antibioticsa 
% patients 
treated with 
antibioticsa 
% medicines 
prescribed from 
the EMLa 
% medicines 
prescribed by 
generic namea 
% patients 
prescribed 
multivitaminsa 
% of patients 
prescribed 
injectionsa 
Average % better (+) 
medicines use over 
time (95% CI) 
Change in 
the number of 
policies implemented 
Direction of better  medicines  use: More (+); Less (−)    Less (−) Less (−) More (+) More (+) Less (−) Less (−) Sign (+/−) changed 
for QUM indicators where 
less use is better  use so 
that “+” = better QUM 
between the second 
and first situation 
analyses 
Bangladesh  (2010, 2014) −16.6 0 
Bhutan (2011, 2015) −19.6 + 8.1 + 1.5 + 2.9 − 10.1 −3.7 + 4.9 (−2.4 to + 12.5) + 2 
Maldives (2011, 2014) − 19.3 −13.8 + 19.3 + 22.8 + 5.6 + 4.8 (− 10.0 to + 19.6) + 3 
Myanmar  (2011, 2014) + 2.0 + 7.1 −7.6 + 11.3 + 13.7 + 4.0 − 3.8 (− 10.6 to + 2.9) + 4 
Nepal (2011, 2014) − 6.3 −2.5 −0.04 −10.5 + 11.7 −3.7 − 1.6 (− 7.8 to + 4.5) 0 
Sri Lanka (2010, 2015) + 7.1 − 7.5 + 13.4 −7.8 + 1.7 (− 6.8 to + 10.1) + 2 
Thailand (2012, 2015) −13.7 − 17.9 + 8.4 + 5.0 − 2.5 + 1.3 + 7.7 (+ 2.0 to + 13.4)** + 7 
Timor-Leste (2012, 2015) −24.1 −13.7 −3.7 −6.4 − 17.9 + 0.1 + 7.6 (− 2.5 to + 17.7) −1 
aThe mean difference between the second and first situational analyses 
**p ≤ 0.05 
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education of prescribers  and adequate  distribution (as 
indicated  by finding  STGs  available at  health  facilities); 
an  MOH  unit  dedicated  to  monitoring and  promoting 
QUM; continuing medical education  (CME) on prescrib- 
ing for health  workers  by MOH; limiting the OTC  avail- 
ability of systemic antibiotics;  not  allowing public sector 
prescribers  to gain revenue  from  the  sales of medicines; 
and   monitoring   advertisements  of   OTC    medicines. 
Other  policies  that  had  a significant  but  smaller  associ- 
ation  with  better   QUM  included:  more   efficient  drug 
supply system (as indicated  by no stock-out problems 
reported);  availability of a national formulary; public 
education programs  on medicines  use; and not  charging 
patients  any registration or consultation fee at health 
facilities. 
The policies associated  with better  QUM  in this study 
are similar to those  policies associated  with better  QUM 
in an analysis of global secondary  data  [16, 17] (exclud- 
ing those  policies  which  were  not  commonly  measured 
in both  studies).  The  one  exception  was that  CME was 
done  by MOH,  and  was associated  with better  QUM  in 
this  study,  but  may  not  have  been  done  by  MOH   in 
countries  included   in  the   previous   analysis  of  global 
data, where CME was associated with poorer  QUM. 
The effectiveness of similar interventions has been 
reported  elsewhere,  including:  education  of prescribers 
[4, 5] and the public [26], an MOH unit dedicated  to 
promoting   QUM    [27],   administrative   interventions 
such  as hospital  drug  and  therapeutic committees 
(DTCs)  [28,  29],  non-allowance  of  prescriber   income 
from   drug   sales   [30],   non-allowance   of   antibiotics 
OTC  [31], and  monitoring of drug  promotional activ- 
ities [32]. As found in analysis of global data where 
provision   of  medicines   free  of  charge  was  associated 
with better use [16, 17], so in this study not charging 
patients  any fees for medicines (or fees that could be 
construed by patients as being for medicines e.g. 
registration and consultation fees) was associated with 
better  use. 
There was a significant moderate to strong positive 
correlation   between   the   number    of   policies 
implemented and the composite  QUM (over six indi- 
cators),  and  for two  of the  individual  QUM  indicators 
(% URTI  cases  prescribed  antibiotics  and  % medicines 
prescribed   by  generic   name).   While   the   effect  sizes 
were  small  for  individual   policies  (< 10%), the  effect 
sizes  associated  with  implementation  of  multiple  pol- 
icies  were  large  (30–95%  over  different  QUM  indica- 
tors)   and   comparable    with   the   largest   intervention 
effects  reported elsewhere  [4, 5]. We  believe  that  the 
data on the possible impacts of multiple policies are 
important  and   likely  to  reflect   a  causal   association. 
This  is  the  second  time  we  have  found  the  correla- 
tions  between   numbers  of  implemented  policies  and 
better QUM measures,  and these analyses were conducted 
in different and independent data-sets  [16, 17]. 
Increased   effect  sizes  with  multiple   (as  opposed   to 
single interventions) have been  reported  in many  litera- 
ture  reviews [4, 5, 33–35]. The  correlations between  the 
composite  QUM indicator  and the number of policies 
implemented  remained   strong   in  both   wealthier   and 
poorer  countries when  the  regression  analysis was 
repeated   for  countries   with  a  GNIpc  above  and  below 
the median  of USD 2230. This finding together  with the 
fact  that  there  was no  correlation between  GNIpc  and 
the  number of policies  implemented suggests  that  it  is 
likely that the better  QUM seen with increasing policy 
implementation was due  to  the  policies  themselves  and 
not due to wealth, as has been found elsewhere [16, 17]. 
The  apparent  improvement  in  QUM   in  association 
with increased policy implementation over time seen in 
Thailand may be a chance finding since the number  of 
facilities  was  small  and   the   same   facilities  were  not 
visited   during   both   visits.  Nevertheless,   Thailand   in- 
creased  its policy implementation more  than  other 
countries over  the  time-period and  similar  results  have 
been  reported   elsewhere  [36, 37].  Therefore,   it  is sug- 
gested  that  the  method   used  in  this  study  to  measure 
QUM  in  relation   to  policy  implementation  may  be  a 
good method  to monitor country  progress  on promoting 
QUM. 
The data analysed in this study were collected from all 
countries during 2-week periods using a pre-designed 
workbook  tool by government staff with facilitation from 
WHO,  were discussed  in each country  and a report  pro- 
duced   and   published   on   WHO/SEARO  website   for 
future  use [21]. The approach  was mandated by Member 
States [38, 39] and proved  relatively cheap and quick, so 
enabling   government   participation   and   action.   This 
study further shows that the data collected from this ap- 
proach   is  sufficient  for  regional  analysis  and  develop- 
ment  of a regional approach  to promote better  QUM. 
 
Limitations 
Although there were moderate to strong correlations 
between  medicines  use  and  policy  implementation  in 
this   study,   causality   cannot   be  proved   and   may  be 
due to co-interventions. Small sample sizes disallowed 
multi-variable    analyses.   Nevertheless,   these   are   the 
best  data  available  on  policy  effectiveness  in  the  pub- 
lic sector in South-East Asia given the absence in all 
countries  of national  longitudinal  data  which  could  be 
used  to  perform   time  series  analysis  to  show  associ- 
ation  or  possibly  prove  causality.  It  is  acknowledged 
that  much  health  care  is provided  in  the  private  sec- 
tor but there was insufficient data to investigate this. 
Nevertheless,    the   findings   are   very   relevant    since 
many  prescribers  work  in  both  the  public  and  private 
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sectors    and    many    private-sector   prescribers    copy 
public-sector ones e.g. private general practitioners 
copying  public-sector specialists. 
The  policy  data,  recorded   in  the  situational   analysis 
country  reports  [21], was collected  by direct  observation 
and  discussion  with  health  officials  and  health  facility 
staff  during  the  country   situational   analysis  visits  and 
thus may be more accurate than data relying on MOH 
questionnaires, as used  elsewhere  [16, 17]. Nevertheless, 
there may be some misclassification since relatively few 
health  facilities were  visited  and  it was not  always easy 
to  interpret whether  a policy was implemented or  not. 
For example, there was enormous variation between 
countries and between  health facilities in the same coun- 
try concerning hospital  DTC  activities, and  the  content 
and extent  of prescriber  CME and public education  pro- 
vided by the MOH. Some policies measured  in this study 
are likely to be effective through association  with other 
health  system factors and policies. For example, the gen- 
eral  lack  of  availability  of  systemic  antibiotics  OTC  in 
Bhutan  and  DPR Korea may be due  to a lack of private 
sector   as  well  as  regulatory   controls.   The  policy  “no 
stock-outs reported” was assumed  to reflect better  drug 
supply which might then impact on QUM. However, a 
situation  of “no  stock-outs” could  itself result  from  bet- 
ter QUM. 
The  prescribing  (QUM)  data  were  collected  by direct 
QUM surveys were done, and this may account for the 
stronger  correlation between  policy implementation and 
QUM  seen  in this  study  compared to previous  analyses 
[16, 17]. 
 
 
Conclusions 
Irrational   use   of  medicines   is  a  serious   problem   in 
South-East  Asia. Essential medicines  policies were found 
to  be  associated   with  better   QUM   and  it  is  recom- 
mended  that  all countries: implement (through adequate 
education and distribution) national STGs, EML and 
formulary; establish an MOH unit dedicated to QUM; 
conduct  CME  on  prescribing  for health  workers  under 
close supervision  of MOH; limit OTC  availability of sys- 
temic  antibiotics;  disallow  public  sector  prescribers   to 
gain revenue  from the sales of medicines; monitor adver- 
tisements  of OTC  medicines;  run  public education cam- 
paigns  on  QUM;  do  not  charge  patients   user  fees  or 
co-payments for medicines  at the  point  of care; and  in- 
vest  in  a  more  efficient  drug  supply  system.  The  situ- 
ational analysis approach allows the relatively quick and 
cheap  collection  of data on QUM  and policy implemen- 
tation  which  can  be used  to monitor progress  and  plan 
future  action. 
 
 
Additional files 
examination   of   treatment   in   30   outpatient   patient    
encounters  (plus  10–30  URTI  cases  where  measured) 
per  facility on  the  day  of  the  visit  using  the  INRUD/ 
WHO  methodology  [23, 24]. Since all six QUM  indica- 
tors  were  collected  in 15 (75%) of the  20 country  situ- 
ational   analysis  visits,  the   QUM   data   may  be  more 
robust   than   what  we  used  in  other   work,  where  we 
relied  on  previously  published  surveys  with  on  average 
only three  QUM  indicators  per  country  [16]. Neverthe- 
less, while every effort was made  to collect the data in a 
standard way, the variation between  countries in docu- 
mentation  of  patient   treatment  and  the  small  sample 
sizes involved may have resulted  in some inaccuracies  in 
the  results.  Furthermore,  some  indicators  such  as injec- 
tion use and antibiotic use in URTI cases could not be 
measured  in some countries and in some health  facilities 
within   a  country.   However,   any   inaccuracies   in   the 
QUM and policy data would tend to weaken the correla- 
tions observed. 
Another  serious  weakness  is that  the  QUM  measure- 
ments   were  based  on  small  convenience   samples  (by 
MOH) of on average 10–11 public health facilities per 
country  visit. Thus, the surveys were not generalisable  to 
whole countries  and no benchmarking of country per- 
formance can be done using these data. Nevertheless, 
implementation of some policies was judged by observa- 
tion   of  what   occurred   in  the   health   facilities  where 
Additional  file 1: Dataset created from extraction of data from country 
situational analysis reports, all available online at: http://www.searo.who.int/ 
entity/medicines/country_situational_analysis/en/ and http:// 
www.searo.who.int/entity/medicines/en/. Excel file of the dataset created 
from data extracted  from the country  situational  analysis reports and which 
was used in the analysis described in this manuscript. (XLSX 13 kb) 
Additional  file 2: Medicines management in healthcare delivery: WHO/ 
SEARO workbook tool and report template for undertaking  a situational 
analysis of medicines management in health care delivery in low and 
middle-income  countries, March 2016. Available online at: 
http://www.searo.who.int/entity/medicines/country_situational_analysis/ 
en/. PDF file of the data collection instrument used to collect data in the 
country  situational  analyses and that was analysed in this manuscript. 
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Abstract
Background: Irrational use of medicines is widespread in the South-East Asia Region (SEAR), where policy implementation
to encourage quality use of medicines (QUM) is often low. The aim was to determine whether public-sector QUM is better
in SEAR countries implementing essential medicines (EM) policies than in those not implementing them.
Methods: Data on six QUM indicators and 25 EM policies were extracted from situational analysis reports of 20
country (2-week) visits made during 2010–2015. The average difference (as percent) for the QUM indicators
between countries implementing versus not implementing specific policies was calculated. Policies associated
with better (> 1%) QUM were included in regression of a composite QUM score versus total number of policies
implemented.
Results: Twenty-two policies were associated with better (> 1%) QUM. Twelve policies were associated with 3.6–
9.5% significantly better use (p < 0.05), namely: standard treatment guidelines; formulary; a government unit to
promote QUM; continuing health worker education on prescribing by government; limiting over-the-counter
(OTC) availability of systemic antibiotics; disallowing public-sector prescriber revenue from medicines sales; not
charging fees at the point of care; monitoring advertisements of OTC medicines; public education on QUM; and a
good drug supply system. There was significant correlation between the number of policies implemented out of
22 and the composite QUM score (r = 0.71, r2 = 0.50, p < 0.05).
Conclusions: Country situational analyses allowed rapid data collection that showed EM policies are associated
with better QUM. SEAR countries should implement all such policies.
Keywords: South-East Asia, Quality use of medicines, Essential medicines policy
Background
Inappropriate (irrational, incorrect, improper, poor qual-
ity) use of medicines is a serious public health problem
world-wide [1–5] that wastes resources and may result
in treatment failure and avoidable adverse drug events,
including antimicrobial resistance [6–8], hospitalisation
and death [9–11]. The World Health Organisation
(WHO) has been promoting the concept of essential
medicines and a range of policies to promote better
quality (rational) use of medicines (QUM) for many
years [12, 13]. The extent to which countries, including
many in South-East Asia, monitor use or implement
these recommended policies vary greatly [14, 15]. A re-
view of interventions to promote better QUM in low
and middle-income countries found that relatively few
had been implemented and that most were small scale
of short duration with small or modest effect [4, 5].
Analysis of secondary data on public-sector medicines
use in primary care (from WHO’s database of medicines
use surveys) and policy implementation as reported by
Ministries of Health (MOH) (from questionnaires sent
to Ministries of Health by WHO) showed that many es-
sential medicines policies are associated with better
QUM and that the more policies are implemented the
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better the use [16, 17]. Policies most strongly associated
with QUM were: undergraduate training of doctors and
nurses in standard treatment guidelines, the ministry of
health having a unit promoting QUM, and provision of
essential medicines free at point of care to all patients
[16, 17].
The need for an integrated health systems approach,
incorporating regular monitoring of medicines use and
the sustainable implementation of multiple policies has
long been recognised [18, 19]. However, development of
such an approach remains elusive in many low and
middle-income countries, where data are scant, infra-
structure is lacking and responsibility for medicines
management often falls between different departments
with no clear accountability [20].
Since 2010 South-East Asian countries of the WHO
have been undertaking 4-yearly rapid situational analyses
of how medicines are used and managed with a view to
developing a more integrated, coordinated health sys-
tems approach to promoting better QUM [21]. This
process consists of rapid systematic data collection on
medicines use and policy implementation by a multi-
disciplinary government team of four to eight people
over 2 weeks using a predesigned workbook tool and
ending with a national workshop to identify priorities
for action [21]. During 2010–2015, all 11 jurisdictions
(all South-East Asia countries including two Indian
States) had conducted at least one situational analysis;
eight had conducted two situational analyses sepa-
rated by a period of 4 years; and the reports pub-
lished on the WHO’s South-East Asia Regional Office
(SEARO) website after government approval [21].
The aim of this paper was to investigate associations
between the adoption (implementation or partial imple-
mentation) of national policies intended to improve
QUM and patterns of medicine use in WHO South-East
Asian countries. The analysis relies on data on medi-
cines use in public-sector primary care, and policy im-
plementation, extracted from the country situational
analysis reports [21]. Specific objectives were to establish
for the WHO South-East Asia region:
1. which policies are associated with better QUM,
2. whether the implementation of more policies is
associated with better QUM, and
3. whether there was any improvement in policy
implementation and QUM in countries that had
undertaken two situational analyses.
Methods
The country reports of the situational analyses published
on the website of the WHO Regional Office for
South-East Asia (WHO/SEARO) [21] were reviewed and
data extracted on QUM in public-sector primary care
and the implementation of policies to encourage appro-
priate use. The methods for conducting country situ-
ational analyses have been described elsewhere [21,
22] and are summarised in Table 1. Briefly, data on
policy implementation was collected by interviews of
health staff and observation, and data on QUM by
prescription survey following the International Net-
work for the Rational Use of Drugs (INRUD)/WHO
methodology [23, 24] at all the health facilities visited.
The methods used to analyse the extracted data
followed similar methods used by first author in
analysing global data and are described elsewhere [16,
17] and summarised below.
A dataset was created (Additional file 1) consisting of
six standard QUM indicators [16, 17] and indicators for
implementation of 25 policies hypothesised to influence
Table 1 Summary of methods used in a country situational
analysis
Background
Development of the situational analysis approach in South-East Asia
was requested by Member States [38, 39] and involves the systematic
collection of data by a government multi-disciplinary team over 2
weeks using a pre-designed workbook tool [21] and supervised by
WHO. The workbook tool (Additional file 2) builds on other tools
[14, 23, 24] and was developed by WHO/SEARO during situational
analyses done in 11 countries during 2010–13 and piloted for use by
government staff in eight countries during 2014–15.
Methods
Visits are made to:
• all major MOH units and other agencies responsible for medicines
management (supply, selection, use, regulation, policy, insurance
and professional training) to understand what policies are in place
and what each unit does.
• healthcare facilities, aiming to visit 20 facilities, two of each type of
public facility (primary care centres and sub-centres, secondary and
tertiary hospitals, with half of the facilities being primary care
centres) plus private pharmacies (results not reported in this paper)
in at least two provinces/regions, as selected by the MOH.
Data collection and Analysis
At the central level, staff are interviewed about the health system,
what their unit does and what policies are in place.
At each health facility (whether hospital or health centre), the team
reviews 30 primary care outpatient encounters (using whatever
documentation is available at the facility, e.g. prescriptions held in the
pharmacy or by the patient, paper slips in the pharmacy, patient
records, or outpatient registers). The means for standard indicators of
medicines use [23, 24] are calculated for each facility and each
category of facility. Also, antibiotic use in 30 outpatient cases of upper
respiratory tract infection is reviewed, although this is difficult in some
countries where diagnosis is not recorded on the prescription. The
basis for a diagnosis of upper respiratory tract infection is also
recorded e.g. acute viral respiratory infection, pharyngitis, sore throat,
rhinitis, runny nose, cough, cold, otitis media, earache, sinusitis, acute
laryngitis and acute bronchitis.
The medicines’ supply and regulatory systems are also reviewed and
health workers interviewed about medicine management policy
implementation.
A descriptive analysis is done each day and presented by the team at
a national workshop at the end of 2 weeks, and a country report
published on the WHO/SEARO website after government approval
[21, 38].
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medicines use [14–17], derived from data collected dur-
ing 20 country situational analysis visits. Since different
provinces or regions and different healthcare facilities
were visited in the countries where two situational ana-
lyses were done, and the visits were separated by 3–
5 years (during which time the implementation of some
policies changed), these situational analyses were treated
as separate records (country-year jurisdictions) in the
dataset.
The QUM indicators (described in Table 2, together
with the direction of more appropriate use) are all
expressed as proportions and include all the indicators
measured in the country situational analyses apart from
one (the average number of drugs per patient). In the
situational analysis reports [21], QUM indicators were
reported as an average for each facility type, but for this
analysis one result per QUM indicator was calculated,
this being the average across all facilities.
The policy indicators (described in Table 3) are all
expressed as categorical yes/no variables and include
all those policies hypothesised to improve the appro-
priate use of medicines [16, 17] for which data were
available in the country situational reports [21] and
for which there were countries with and without the
policy (for comparison). Some policies hypothesised
to influence prescribing were not implemented by any
country (e.g. monitoring all drug promotional activ-
ities), but if possible, similar more limited policies
were substituted (e.g. monitoring of advertisements
restricted to over-the-counter drugs). Where policy
implementation was expressed as a range of values,
the policy was converted to a yes/no value. For ex-
ample, “some” public education and “some” health
worker training was regarded as “yes” when assessing
whether a country had implemented these policies.
Details of decisions on whether a policy was marked
as present or not can be seen in Table 3. Since coun-
try wealth may be a potential confounder (being asso-
ciated with both better QUM and greater policy
implementation), data on gross national income per
capita (GNIpc) were extracted for each country in the
year of the situational analysis from the United
Nations (UN) Country Profile Data [25].
Analyses
Analyses were done in Excel 2016 and Epi Info version
7.2.1.0. Univariate analyses, with each policy as the unit
of analysis, were used to identify policies that were asso-
ciated with better QUM. The mean difference (expressed
as a percentage) for each QUM indicator between
“countries” (country-year jurisdiction) implementing and
not implementing a specific policy was calculated. The
directionality of “better” or “worse” use was aligned for
each of the six QUM indicators and an average (overall)
difference calculated for each specific policy, whereby a
positive (+) number indicates “better” use and a minus
(−) number indicates “worse” use. The mean differences
for each QUM indicator, and the average difference
across all QUM indicators for each policy were calcu-
lated and represent an estimate of the quantitative
impact of each policy. Head-to-head comparisons of the
impact of different policies and further multiple compar-
isons were not done.
Correlations of multiple policies with QUM indicators,
where the “country-year jurisdiction” was the unit of
analysis, were performed to see if adoption (implementa-
tion or partial implementation) of more policies was
associated with better QUM. Since various policies are
likely to impact differently on different QUM indicators,
and to gain an idea of the overall impact on QUM by
the package of policies that any one country was imple-
menting in one specific year, a composite QUM variable
was derived, in the same manner as has been done else-
where [16]. Use of a composite QUM variable allowed
comparison of data across all 20 situational analyses
rather than only 15, since some QUM indicators were
not measured in five situational analyses. For each indi-
vidual QUM variable, we calculated how far that coun-
try’s value (referred to as “country-year” – see text) lay
above or below the mean value from all “country-years”
and then converted this difference into standard devi-
ation units. The average of the standard deviation unit
increments across all six QUM indicators for each
country-year was calculated and this was then regressed
against the number of implemented policies that were
associated with an effect size of more than 1% (22 out of
25 policies) as estimated from the univariate analysis.
Although countries implement each policy differently,
the adoption of more policies is likely to reflect stronger
intention to promote QUM, which may be reflected
variously by different QUM indicators. Hence, individual
QUM indicators were also regressed on the number of
policies a country implemented. Since there may be
Table 2 Quality Use of Medicines (QUM) indicators and direction
of better use
QUM Indicator Direction of better
use
% Upper Respiratory Tract Infection (URTI) cases
(patients) treated with antibiotics
Less
% cases (patients) treated with antibiotics Less
% prescribed medicines from the national Essential
Medicines List (EML)
More
% medicines prescribed by generic name More
% cases (patients) treated with multivitamins Less
% cases (patients) treated with an injection Less
Six standard indicators of quality of medicines use [23, 24] expressed as
proportions and reported in 85–100% of the situational analyses
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Table 3 Medicine Policy variables with information on how a policy was judged to be present or not
Policies recommended to improve medicines usea Criteria to determine whether a policy was adopted (implemented or partially
implemented) in a country
National structures, medicines policies and monitoring
1 National MOH unit on promoting rational use of medicines Policy was marked “yes” if there was any unit, even if very small and consisting of
only 1–2 persons, or an executive committee with responsibility for promoting quality
use of medicines.
2 Presence of a Drug and Therapeutic Committee (DTC) in
most referral hospitals
Policy was marked “yes” if more than half of referral hospitals visited had a DTC
which had met in the last year (even if not very active) and there was an MOH
mandate for DTCs.
3 National strategy to contain antimicrobial resistance Policy was marked “yes” if there was any policy document endorsed by MOH on
AMR containment.
4 Presence of National Drug Information Centre Policy was marked “yes” if any national drug information centre existed, even if the
centre was not very active and did not offer 24-hour emergency information.
5 Prescription audit in the last 2 years Policy was marked “yes” even if the audit had only been undertaken in the health
facilities of some districts, but including at least one of the districts visited during
the situational analysis.
Educational policies
6 Undergraduate training of prescribers on the National
Essential Medicines List (EML)
Policy was marked “yes” even if only some training institutions included the EML in
the curriculum.
7 Undergraduate training of prescribers on the National
Standard Treatment Guidelines (STGs)
Policy was marked “yes” even if only some training institutions included the STG in
the curriculum.
8 Continuing medical education (CME) of prescribers by
MOH
Policy was marked as “yes” even if only some prescribers received CME on general
prescribing in adults and/or children. The Antibiotic SMART Use program in
Thailand, INRUD training activities in Nepal and the training activities of the
National Institute of Health (INS) in Timor-Leste are examples of CME by the MOH
[21, 37].
9 Public education on medicines use in last 2 years Policy was marked “yes” if any district populations had received public education.
Managerial Policies
10 National Essential Medicines List updated in the last 2 years Was not hypothesized to influence antibiotic use.
11 National Standard Treatment Guidelines updated in the last
2 years
Policy was marked” yes” if there was any kind of officially published book
containing national treatment guidelines, but not for disease protocols on posters
or pamphlets.
12 National Standard Treatment Guidelines (STGs) found in
some health facilities (indicator of STG implementation).
Policy was marked “yes” if the national STGs (published book) were observed in
more than two facilities visited.
13 National Formulary available Policy was marked “yes” if any national formulary was observed in any facility.
14 Generic prescribing policy in public sector Policy was marked “yes” if there was any initiative described to encourage generic
prescribing. Was not hypothesized to influence antibiotic use.
15 Generic substitution in public sector Policy was marked “yes” if generic substitution was both legal and seen to occur.
Was not hypothesized to influence antibiotic use.
16 Prescriber workload low or moderate Low/moderate workload defined as less than 60 patients per prescriber per day, as
reported by prescribers or as observed in patient registers.
Supply system
17 Public sector procurement limited to only EML medicines Policy was marked “yes” if public sector procurement limited to EML medicines was
reported at the central level and observed at the health facilities visited. Indicator of
implementation of the EML.
18 No medicines stock-out problems reported in the health
facilities visited
Policy was marked “yes” if health workers at the facilities visited stated that there
were no stock-out problems. Indicator of the quality of the supply system which
may impact on use.
Economic Policies
19 NO Drug sales revenue used to supplement prescriber
income
Policy was marked “no” if prescribers were observed selling drugs in the public
sector, as was the case in one country in 1 year.
20 No registration or consultation fee All countries stated that they dispensed drugs free of charge to all patients in
public facilities if medicines were available, but some charged registration or
consultation fees which could be perceived by patients as payment for treatment.
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correlation between the results of different situational
analyses done in the same country, a sensitivity analysis
was done by restricting the regression analysis to the lat-
est situational analysis of the country.
The impact of country economic status was assessed
by including Gross National Income per capita (GNIpc)
into multiple linear regression analyses and by repeating
the regression analyses for countries with GNIpc above
and below the median of USD 2230.
Finally, in those countries where a situational analysis
was done twice, the mean difference between situational
analyses, for each of the six QUM indicators, was calcu-
lated to see whether there had been any change in QUM
over time, and whether any change was accompanied by
a corresponding change in the number of policies
implemented.
Results
Data were extracted from 20 situational analysis reports
covering all 11 countries of the WHO South-east Asia
region – two reports from eight countries in different
years, two reports from India (one North Indian and one
South Indian state in the same year) and one report each
from two countries (Democratic Peoples’ Republic
[DPR] of Korea and Indonesia). QUM data for all six in-
dicators were extracted from 15 country-visit reports,
with 1–2 QUM variables missing from four reports
(concerning injection use, prescribing from the Essential
Medicines List [EML] and antibiotic use in upper re-
spiratory tract infection [URTI] cases), and 5 out of six
QUM indicators missing from one early report
(Bangladesh 2010). A total of 206 public-sector health
facilities were visited (average of 10–11 public-sector
health facilities per country-visit, half of which were pri-
mary healthcare centres) and 30 prescriptions per facility
were examined to estimate five of the six QUM indica-
tors. The QUM indicator concerning the % URTI cases
treated with antibiotics was estimated from visits to 151
public-sector health facilities (average of 7–8 facilities
per country visit) with an average of 23 URTI prescrip-
tions examined per facility. In two countries (Sri Lanka
2010 and Bangladesh 2010) no data on antibiotic use in
URTI was available, in two countries (Bhutan 2011 and
Maldives 2011) data on antibiotic use in URTI was avail-
able in only two health facilities and in one country
(Indonesia 2011) from only three health facilities. Policy
data for all 25 indicators were extracted from all 20
country-visit reports.
Comparison of QUM indicators in countries with and
without specific policies
Table 4 shows the mean differences for each of the six
QUM indicators, and the average difference across all
six QUM indicators, between countries that did and did
not implement the 25 policies hypothesised to be associ-
ated with better use. Figure 1 shows the mean difference
(with 95% confidence interval)) across all six QUM indi-
cators for each of the 25 policies. Twenty-two out of 25
policies were associated with better QUM, although in
many cases the differences were small. Twelve policies
were associated with statistically significantly (p < 0.05)
better QUM of more than 3.6% – namely not charging
patients any user fee or copayment for medicines at the
point of care, undergraduate education of prescribers on
the national treatment guidelines (STGs), distribution of
STGs to health facilities (as demonstrated by finding
Table 3 Medicine Policy variables with information on how a policy was judged to be present or not (Continued)
Policies recommended to improve medicines usea Criteria to determine whether a policy was adopted (implemented or partially
implemented) in a country
21 No user fee or copayment at the point of care Although all countries officially dispensed drugs free of charge in public facilities,
some types of facility, generally hospitals, charged a user fee or co-payment for
drugs at the point of care.
Regulatory policies
22 Systemic antibiotics generally not available over-the-
counter (OTC)
Systemic antibiotics could be got OTC in all countries but were generally
unavailable in Bhutan and DPR Korea where the private sector is very small, and
effort is made to enforce the drug schedules.
23 Regulation of advertisements for OTC drugs medicines No countries were monitoring all drug promotional activities, but some did monitor
advertising of OTC drugs.
Human resource policies
24 Prescribing by doctors (as opposed to other staff) in public
primary care
Policy was marked “yes” if doctors were observed to be prescribing in the primary
care facilities visited. Where doctors were not prescribing paramedical staff or
nurses generally prescribed, although in one country unqualified staff sometimes
prescribed.
25 No prescribing by staff with less than 1 month’s training
in public primary care
Policy was marked “yes” if no unqualified staff were observed to prescribe.
aIncludes all the policy questions, hypothesised to act on the quality of medicines use, as hypothesised elsewhere [16, 17] and found in the situational analysis
reports [21]
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Table 4 Differences in medicine use between countries with and without each of 25 policies hypothesised to be associated with
better use
Policy Number of
countries with
policy
(out of 20)a
% URTI
cases
treated with
antibiotics
% patients
treated
with
antibiotics
% medicines
prescribed
from the
EML
% medicines
prescribed by
generic name
% patients
prescribed
multivitamins
% of
patients
prescribed
injections
Average % better
(+) medicines use
with policy
(95% CI)
Direction of better
medicines use:
More (+); Less (−)
Less (−) Less (−) More (+) More (+) Less (−) Less (−) Sign changed
where less use is
better use
No user fee for drugs
at most public health
facilities
17 −9.6 + 0.1 + 9.5 + 31.2 −7.5 + 0.8 9.5* (0.2 to 18.7)
Undergraduate
education of
prescribers on STGs
5 −15.9 −5.2 + 12.0 + 22.0 − 1.1 + 0.9 9.2* (2.1 to 16.4)
Systemic antibiotics
mostly not available
OTC
3 −16.0 − 5.2 + 12.0 + 22.0 − 1.3 + 1.4 9.2* (1.9 to16.4)
MOH unit on Rational
Use of Medicines
established
3 −17.3 −10.9 + 0.1 + 19.7 + 0.9 −6.9 9.0* (2.1 to 15.9)
Some public-sector
prescriber CME by
MOH
8 −7.5 −1.6 + 5.7 + 21.9 − 8.7 − 4.8 8.4* (2.7 to 14.0)
Advertisements for
OTC drugs monitored
7 −14.5 −3.8 + 4.0 + 15.5 − 2.0 − 8.3 8.0* (3.4 to 12.7)
Public sector generic
prescribing policy
9 −3.9 −1.6 + 9.8 + 35.1 + 0.4 + 2.2 8.0 (− 3.2 to 19.1)
No drug revenue for
public sector
prescribers
19 −19.1 −2.7 −2.2 + 18.8 − 7.0 −6.7 7.8* (0.1 to 15.5)
MOH prescribing
survey done in the last
2 years
7 −4.7 −1.2 + 4.6 + 28.6 + 2.7 − 7.7 7.4 (− 1.4 to 16.2)
STGs found in some
public health facilities
5 − 11.4 −9.7 + 6.1 + 17.8 + 1.4 + 2.4 6.9* (0.6 to 13.1)
No public-sector
registration or
consultation fee
12 −13.0 −3.3 + 5.6 + 15.2 + 2.5 − 5.6 6.7* (1.5 to 11.9)
Some public education
on medicines use in
the last 2 years
5 −11.7 −7.4 + 2.5 + 8.9 −5.0 + 2.4 5.5* (1.5 to 9.5)
DTCs in most public
referral hospitals
8 −1.7 + 3.2 −2.5 + 15.2 −9.3 − 10.3 5.1 (− 0.9 to 11.2)
Generic substitution in
the public sector
15 + 6.0 + 7.8 + 16.1 + 21.8 −2.8 + 0.4 4.4 (−5.2 to 14.0)
No drug stock-out
problems reported
9 −11.6 −3.8 −0.1 − 1.4 −2.3 − 7.9 4.5* (0.1 to 8.0)
National Formulary
available
7 −8.7 −0.7 −3.4 + 6.1 − 5.9 − 3.7 3.6* (0.2 to 7.1)
National EML updated
in the last 2 years
12 −6.0 −0.7 + 16.1 − 0.4 + 1.2 + 2.2 3.2 (− 2.4 to 8.7)
Undergraduate
education of doctors
on the EML
6 −9.9 + 0.6 −3.5 + 1.7 −3.7 −6.8 3.0 (−0.9 to 6.9)
No public-sector un
qualified prescribers
18 −5.8 −6.5 + 8.4 + 9.8 + 8.4 + 8.6 2.3 (−4.5 to 9.0)
National STG updated
in the last 2 years
7 + 5.8 + 6.9 + 6.9 + 20.1 + 5.5 − 1.0 1.6 (−6.7 to 10.0)
Holloway et al. BMC Health Services Research  (2018) 18:526 Page 6 of 16
them in facilities), a Ministry of Health (MOH) unit ded-
icated to promoting QUM, continuing education on
prescribing for health workers by MOH, general
non-availability of systemic antibiotics over-the-counter
(OTC), monitoring of advertisements for OTC medi-
cines, no revenue from medicine sales for public sector
prescribers, having no stock-out problems, public
education and having a national formulary. For the 22
(out of 25) policies associated with better overall
QUM of more than 1%, 96 (73%) of a possible 132
comparisons (6 QUM indicators × 22 policies) were
associated with better QUM.
Table 4 Differences in medicine use between countries with and without each of 25 policies hypothesised to be associated with
better use (Continued)
Policy Number of
countries with
policy
(out of 20)a
% URTI
cases
treated with
antibiotics
% patients
treated
with
antibiotics
% medicines
prescribed
from the
EML
% medicines
prescribed by
generic name
% patients
prescribed
multivitamins
% of
patients
prescribed
injections
Average % better
(+) medicines use
with policy
(95% CI)
National AMR
Containment Strategy
4 −1.3 −3.7 −10.0 + 2.2 − 3.4 − 8.3 1.5 (− 3.4 to 6.4)
Public procurement
limited to EML drugs
only (excl. DPRK)
15 + 12.6 + 12.5 + 15.5 + 22.3 + 0.2 + 3.4 1.5 (− 10.1 to 13.1)
National Drug
Information Centre
2 + 7.2 −1.5 −3.9 + 11.6 + 3.4 + 15.7 − 2.8 (− 10.1 to 4.4)
Public sector PHC
prescribing by doctors
13 + 1.9 + 3.5 −2.3 −10.3 −4.0 + 5.8 −3.3 (− 7.1 to 0.4)
Prescriber patient
load moderate or
low (< 60 patients
/prescriber/day)
12 − 10.9 −8.7 −5.4 −6.3 + 27.2 + 7.9 − 4.5 (− 15.5 to 16.5)
*p ≤ 0.05
aSample size applies to the number of countries (out of 20) that had adopted the policy. The number of countries with and without policies for each individual
QUM indicator varies slightly as certain QUM indicators were not measured in 5 country visits
OTC Over-the-counter, STG Standard treatment guidelines, MOH Ministry of health, CME Continuing medical education, DTC Drug and therapeutic committee, EML
Essential medicines list, AMR Antimicrobial resistance, DPRK Democratic People’s Republic of Korea (which had no published EML)
Fig. 1 Differences in medicines use between countries with and without medicines policies. STG = Standard Treatment Guidelines; OTC = Over-
the-Counter; MOH =Ministry of Health; CME = Continuing Medical Education; DTC = Drug and Therapeutic Committee; EML = Essential Medicines
List; AMR = Antimicrobial Resistance; PHC = Primary Health Care
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Some policies had large effects on one particular
QUM indicator, but not on overall use (as judged by
six QUM indicators). Generic prescribing policies
were associated with greater generic prescribing;
implementing the national EML (as indicated by hav-
ing an updated EML and limiting public procurement
to EML drugs) was associated with greater prescribing
of EML medicines. However, low to modest prescriber
workload (as defined by seeing less than 60 patients
per day) was not associated with better overall QUM,
although it was associated with lower antibiotic use.
Effects of multiple policies and national wealth
Figure 2 shows a scatter plot of the composite QUM indi-
cator and the number of policies implemented (out of 22
policies associated with better QUM) for 20 situational ana-
lysis visits (country-years). There was moderate to strong
positive correlation between the number of essential medi-
cines policies implemented and the composite QUM indi-
cator (r = 0.71, r2 = 0.50, p < 0.05). In sensitivity analyses
(not shown graphically) the correlation increased when
GNIpc was included in the regression analysis (r = 0.75, r2
= 0.57, p < 0.05) and the correlation was moderate to strong
in the 10 country-visits with GNIpc above USD 2230 (r =
0.76, r2 = 0.58, p < 0.05) and below USD 2230 (r = 0.69, r2 =
0.48, p < 0.05). Furthermore, confining the regression ana-
lysis to data from the most recent situational analyses in 12
states (all 11 countries including 2 Indian states), in order
to take account of possible clustering of results from the
same site, also showed moderate to strong correlation
between the composite QUM indicator and the number of
essential medicines policies (r = 0.71, r2 = 0.50, p < 0.05).
Figures 3, 4, 5, 6, 7 and 8 show the scatter plots
for the individual QUM indicators versus policy im-
plementation. Regression analyses of individual QUM
indicators and the number of policies (out of 22) im-
plemented showed that with an increasing number of
essential medicines policies implemented there was:
an increase in the % prescribed medicines belonging
to the EML (r = 0.46, r2 = 0.21, p > 0.05) (Fig. 3); an
increase in the % medicines prescribed by generic
name (r = 0.62, r2 = 0.38, p < 0.05) (Fig. 4); a decrease
in the % patients prescribed injections (r = − 0.24, r2 =
0.06, p > 0.05) (Fig. 5) and a decrease in the % URTI
cases prescribed antibiotics (r = − 0.42, r2 = 0.18, p >
0.05) (Fig. 6). There was virtually no change in the %
patients treated with antibiotics (r = − 0.1, r2 = 0.01,
p > 0.05) (Fig. 7) or vitamins (r = − 0.1, r2 = 0.02, p >
0.05) (Fig. 8) with increasing number of policies im-
plemented. In a sensitivity analysis where policies not
hypothesised to influence antibiotic use were excluded
(2 policies on generic prescribing and substitution
and 3 policies on EML implementation), a stronger
association was found between the number of policies
(out of 17) implemented and the % URTI cases pre-
scribed antibiotics (r = − 0.49, r2 = 0.24, p < 0.05).
Changes over time
In seven of the eight countries where a situational ana-
lysis had been done twice, separated by a period of 3–
Fig. 2 Scatter plot of composite QUM score versus number of policies (out of 22) implemented
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Fig. 3 % prescribed medicines from the Essential Medicines List versus number of policies (out of 22) implemented
Fig. 4 % medicines prescribed by generic name versus number of policies (out of 22) implemented
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5 years, the average mean differences over time for
the six individual QUM indicators and the average
mean difference over the six QUM indicators, to-
gether with any change in the number of policies im-
plemented are shown in Table 5. The data for
Bangladesh were excluded because five of the six
QUM indicators were missing from the first situ-
ational analysis in 2010. The data show a significant
improvement in QUM together with increased policy
implementation in Thailand, while in other countries
there was no significant change in QUM and policy
implementation. However, the small sample sizes
Fig. 5 % patients prescribed injections versus number of policies (out of 22) implemented
Fig. 6 % Upper Respiratory Tract Infection cases prescribed antibiotics versus number of policies (out of 22) implemented
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(concerning health facilities and patient encounters)
preclude further interpretation of the data.
Discussion
This study has two important findings. Firstly, some pol-
icies were associated with significantly better QUM; and
secondly the more of these policies a country imple-
mented the better was the QUM.
Policies statistically significantly associated with more
than 7% better overall QUM were: not charging patients
any user fee or co-payment for medicines at the point of
care; implementation of STGs through undergraduate
Fig. 7 % patients prescribed antibiotics versus number of policies (out of 22) implemented
Fig. 8 % patients prescribed vitamins versus number of policies (out of 22) implemented
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education of prescribers and adequate distribution (as
indicated by finding STGs available at health facilities);
an MOH unit dedicated to monitoring and promoting
QUM; continuing medical education (CME) on prescrib-
ing for health workers by MOH; limiting the OTC avail-
ability of systemic antibiotics; not allowing public sector
prescribers to gain revenue from the sales of medicines;
and monitoring advertisements of OTC medicines.
Other policies that had a significant but smaller associ-
ation with better QUM included: more efficient drug
supply system (as indicated by no stock-out problems
reported); availability of a national formulary; public
education programs on medicines use; and not charging
patients any registration or consultation fee at health
facilities.
The policies associated with better QUM in this study
are similar to those policies associated with better QUM
in an analysis of global secondary data [16, 17] (exclud-
ing those policies which were not commonly measured
in both studies). The one exception was that CME was
done by MOH, and was associated with better QUM in
this study, but may not have been done by MOH in
countries included in the previous analysis of global
data, where CME was associated with poorer QUM.
The effectiveness of similar interventions has been
reported elsewhere, including: education of prescribers
[4, 5] and the public [26], an MOH unit dedicated to
promoting QUM [27], administrative interventions
such as hospital drug and therapeutic committees
(DTCs) [28, 29], non-allowance of prescriber income
from drug sales [30], non-allowance of antibiotics
OTC [31], and monitoring of drug promotional activ-
ities [32]. As found in analysis of global data where
provision of medicines free of charge was associated
with better use [16, 17], so in this study not charging
patients any fees for medicines (or fees that could be
construed by patients as being for medicines e.g.
registration and consultation fees) was associated with
better use.
There was a significant moderate to strong positive
correlation between the number of policies
implemented and the composite QUM (over six indi-
cators), and for two of the individual QUM indicators
(% URTI cases prescribed antibiotics and % medicines
prescribed by generic name). While the effect sizes
were small for individual policies (< 10%), the effect
sizes associated with implementation of multiple pol-
icies were large (30–95% over different QUM indica-
tors) and comparable with the largest intervention
effects reported elsewhere [4, 5]. We believe that the
data on the possible impacts of multiple policies are
important and likely to reflect a causal association.
This is the second time we have found the correla-
tions between numbers of implemented policies and
better QUM measures, and these analyses were conducted
in different and independent data-sets [16, 17].
Increased effect sizes with multiple (as opposed to
single interventions) have been reported in many litera-
ture reviews [4, 5, 33–35]. The correlations between the
composite QUM indicator and the number of policies
implemented remained strong in both wealthier and
poorer countries when the regression analysis was
repeated for countries with a GNIpc above and below
the median of USD 2230. This finding together with the
fact that there was no correlation between GNIpc and
the number of policies implemented suggests that it is
likely that the better QUM seen with increasing policy
implementation was due to the policies themselves and
not due to wealth, as has been found elsewhere [16, 17].
The apparent improvement in QUM in association
with increased policy implementation over time seen in
Thailand may be a chance finding since the number of
facilities was small and the same facilities were not
visited during both visits. Nevertheless, Thailand in-
creased its policy implementation more than other
countries over the time-period and similar results have
been reported elsewhere [36, 37]. Therefore, it is sug-
gested that the method used in this study to measure
QUM in relation to policy implementation may be a
good method to monitor country progress on promoting
QUM.
The data analysed in this study were collected from all
countries during 2-week periods using a pre-designed
workbook tool by government staff with facilitation from
WHO, were discussed in each country and a report pro-
duced and published on WHO/SEARO website for
future use [21]. The approach was mandated by Member
States [38, 39] and proved relatively cheap and quick, so
enabling government participation and action. This
study further shows that the data collected from this ap-
proach is sufficient for regional analysis and develop-
ment of a regional approach to promote better QUM.
Limitations
Although there were moderate to strong correlations
between medicines use and policy implementation in
this study, causality cannot be proved and may be
due to co-interventions. Small sample sizes disallowed
multi-variable analyses. Nevertheless, these are the
best data available on policy effectiveness in the pub-
lic sector in South-East Asia given the absence in all
countries of national longitudinal data which could be
used to perform time series analysis to show associ-
ation or possibly prove causality. It is acknowledged
that much health care is provided in the private sec-
tor but there was insufficient data to investigate this.
Nevertheless, the findings are very relevant since
many prescribers work in both the public and private
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sectors and many private-sector prescribers copy
public-sector ones e.g. private general practitioners
copying public-sector specialists.
The policy data, recorded in the situational analysis
country reports [21], was collected by direct observation
and discussion with health officials and health facility
staff during the country situational analysis visits and
thus may be more accurate than data relying on MOH
questionnaires, as used elsewhere [16, 17]. Nevertheless,
there may be some misclassification since relatively few
health facilities were visited and it was not always easy
to interpret whether a policy was implemented or not.
For example, there was enormous variation between
countries and between health facilities in the same coun-
try concerning hospital DTC activities, and the content
and extent of prescriber CME and public education pro-
vided by the MOH. Some policies measured in this study
are likely to be effective through association with other
health system factors and policies. For example, the gen-
eral lack of availability of systemic antibiotics OTC in
Bhutan and DPR Korea may be due to a lack of private
sector as well as regulatory controls. The policy “no
stock-outs reported” was assumed to reflect better drug
supply which might then impact on QUM. However, a
situation of “no stock-outs” could itself result from bet-
ter QUM.
The prescribing (QUM) data were collected by direct
examination of treatment in 30 outpatient patient
encounters (plus 10–30 URTI cases where measured)
per facility on the day of the visit using the INRUD/
WHO methodology [23, 24]. Since all six QUM indica-
tors were collected in 15 (75%) of the 20 country situ-
ational analysis visits, the QUM data may be more
robust than what we used in other work, where we
relied on previously published surveys with on average
only three QUM indicators per country [16]. Neverthe-
less, while every effort was made to collect the data in a
standard way, the variation between countries in docu-
mentation of patient treatment and the small sample
sizes involved may have resulted in some inaccuracies in
the results. Furthermore, some indicators such as injec-
tion use and antibiotic use in URTI cases could not be
measured in some countries and in some health facilities
within a country. However, any inaccuracies in the
QUM and policy data would tend to weaken the correla-
tions observed.
Another serious weakness is that the QUM measure-
ments were based on small convenience samples (by
MOH) of on average 10–11 public health facilities per
country visit. Thus, the surveys were not generalisable to
whole countries and no benchmarking of country per-
formance can be done using these data. Nevertheless,
implementation of some policies was judged by observa-
tion of what occurred in the health facilities where
QUM surveys were done, and this may account for the
stronger correlation between policy implementation and
QUM seen in this study compared to previous analyses
[16, 17].
Conclusions
Irrational use of medicines is a serious problem in
South-East Asia. Essential medicines policies were found
to be associated with better QUM and it is recom-
mended that all countries: implement (through adequate
education and distribution) national STGs, EML and
formulary; establish an MOH unit dedicated to QUM;
conduct CME on prescribing for health workers under
close supervision of MOH; limit OTC availability of sys-
temic antibiotics; disallow public sector prescribers to
gain revenue from the sales of medicines; monitor adver-
tisements of OTC medicines; run public education cam-
paigns on QUM; do not charge patients user fees or
co-payments for medicines at the point of care; and in-
vest in a more efficient drug supply system. The situ-
ational analysis approach allows the relatively quick and
cheap collection of data on QUM and policy implemen-
tation which can be used to monitor progress and plan
future action.
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